STAAR Surgical AG
Beschreibung
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years.
The company offers the EVO Visian implantable Collamer® lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer Lens or "ICL". Nearly 600,000 Visian ICLs have been implanted to date.
It also provides minimally invasive intraocular lenses (IOLs), including foldable IOLs for use in minimally invasive cataract surgical procedures; aspheric IOLs that produce a clearer image than traditional spherical lenses; nanoFLEX IOL, a single piece Collamer aspheric optic; and Toric IOLs for cataract patients, as well as preloaded injectors for use in cataract surgery. In addition, the company sells surgical products, and other related instruments and devices, as well as injector parts; and manufactures AquaFlow devices for the treatment of glaucoma. It markets its products to health care providers, including surgical centers, hospitals, managed care providers, health organizations, group purchasing organizations, and government facilities primarily under the STAAR, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, Epiphany, and AquaFlow trademarks. The company sells products directly through its sales representatives in the United States, Canada, Japan, Germany, the United Kingdom, and Spain, as well as through independent distributors in approximately 60 countries. STAAR Surgical Company was founded in 1982 and is headquartered in Monrovia, California.
STAAR® developed, patented, and licensed the first foldable intraocular lens, or IOL, for cataract surgery. Made of pliable material, the foldable IOL permitted surgeons for the first time to replace a cataract patient’s natural lens with minimally invasive surgery. The foldable IOL became the standard of care for cataract surgery throughout the world. STAAR introduced its first versions of the lens, made of silicone, in 1991.
In 1996 STAAR began selling the Visian ICL® outside the U.S. Made of STAAR’s proprietary biocompatible Collamer® lens material, the ICL is implanted behind the iris and in front of the patient’s natural lens to treat refractive errors such as myopia, hyperopia, and astigmatism. The ICL received CE Mark in 1997, permitting sale in countries that require the European Union CE Mark, and it received FDA approval for the treatment of myopia in the U.S. in December 2005.
STAAR sells EVO Visian ICL and Visian ICL family of lenses in more than 75 countries, and it has been implanted in more than 1,000,000 eyes worldwide.
---
STAAR Surgical ist ein expandierendes internationales MedTech-Unternehmen, das sich seit über 30 Jahren ausschliesslich der Entwicklung, Herstellung und Vermarktung von innovativen und hochwertigen Implantaten mit den zugehörigen Einführsystemen für die Augenchirurgie widmet.